(Q39763096)

English

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

0 references

quality of life

1 reference

based on heuristic

inferred from title

8

object named as

S Zweegman

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Henk M. Lokhorst

11

object named as

H M Lokhorst

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Silvia G R Verelst

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

F Termorshuizen

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

C A Uyl-de Groot

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

M R Schaafsma

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

A H M Ammerlaan

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

S Wittebol

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

H A M Sinnige

7

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

M van Marwijk Kooy

9

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

R van der Griend

10

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

P Sonneveld

12

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

P W Wijermans

13

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON)

14

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

7 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

90

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1427-1439

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1224-1

21 January 2018

Identifiers

10.1007/S00277-011-1224-1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39763096&oldid=2090054863"